Brain Cancer Clinical Trials in Los Angeles

Showing 81-100 of 152 trials

Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

NCT02336165

This is an ongoing Phase 2, open-label, multicenter, non-randomized study of MEDI4736 (durvalumab) in subjects with glioblastoma (GBM) enrolled into 5 non-comparative cohorts. Primary study objectives, which vary by cohort due to differences in subject populations, include evaluation of the clinical efficacy as measured by the overall survival (OS) rate at 12 months (Cohort A), progression-free survival (PFS) at 6 months (Cohorts B, B2, and B3), and OS at 6 months (Cohort C). For all cohorts, secondary objectives include evaluation of the safety/tolerability and clinical efficacy of study treatment, and exploratory objectives include evaluation of the neurologic function and correlative biomarkers.

Glioblastoma

Ludwig Institute for Cancer Research159 participantsStarted Feb 2015

Los Angeles, California, United States • San Francisco, California, United States • Baltimore, Maryland, United States +5 more locations

SUSPENDEDNA< 1 mile

The Use of Navigated Transcranial Magnetic Stimulation (nTMS) in the Inhibition of Neurofunctional Regions of Interest

NCT04209023

The purpose of this study is to investigate the efficacy of task inhibition during TMS to confirm brain region localization. This study could provide an effective pathway for neurofunctional landmark confirmation that may be useful in a number of treatment modalities and medical considerations.

Brain TumorSurgery

Neurological Associates of West Los Angeles10 participantsStarted Dec 2023

Los Angeles, California, United States

Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

The Use of Navigated Transcranial Magnetic Stimulation (nTMS) in the Inhibition of Neurofunctional Regions of Interest

Brain Cancer Trials in Other Cities

Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma

Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

UNITE Study: Understanding New Interventions With GBM ThErapy

Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma

Safety Study of Afatinib for Brain Cancer

Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer

Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)

Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)

Other Conditions in Los Angeles